Prostate Cancer Treatment–Health Professional Version (PDQ®)

SECTIONS

Changes to This Summary (03/17/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview for Prostate Cancer

Added Conventional versus hypofractionated external-beam radiation therapy as a new subsection.

Stage I Prostate Cancer Treatment

Updated Wilt et al. as reference 14.

Stage III Prostate Cancer Treatment

Added text to provide evidence about continuous versus intermittent hormonal therapy, which included a systematic review of 15 randomized trials that compared continuous versus intermittent androgen deprivation therapy (ADT) for patients with advanced or recurrent prostate cancer and found no significant difference in overall survival (OS), prostate cancer-specific survival, and progression-free survival (PFS); the meta-analysis fulfilled prespecified criteria for noninferiority of OS (cited Magnan et al. as reference 38 and level of evidence 1iiA). Also added that there was little difference in patient-reported quality of life (QOL).

Stage IV Prostate Cancer Treatment

Added text to state that the addition of chemotherapy has been shown in randomized trials to improve OS compared with hormonal therapy alone.

Added text to state that in one trial, 790 patients with metastatic, hormone-sensitive disease were randomly assigned to receive ADT with or without docetaxel and provided median follow-up data (cited Sweeney et al. as reference 3 and level of evidence 1iiA).

Added text to provide evidence about continuous versus intermittent hormonal therapy, which included a systematic review of 15 randomized trials that compared continuous versus intermittent ADT for patients with advanced or recurrent prostate cancer and found no significant difference in OS, prostate cancer-specific survival, and PFS; the meta-analysis fulfilled prespecified criteria for noninferiority of OS (cited Magnan et al. as reference 38 and level of evidence 1iiA). Also added that there was little difference in patient-reported QOL.

Recurrent Prostate Cancer Treatment

Added text to provide evidence about continuous versus intermittent hormonal therapy, which included a systematic review of 15 randomized trials that compared continuous versus intermittent ADT for patients with advanced or recurrent prostate cancer and found no significant difference in OS, prostate cancer-specific survival, and PFS; the meta-analysis fulfilled prespecified criteria for noninferiority of OS (cited Magnan et al. as reference 17 and level of evidence 1iiA). Also added that there was little difference in patient-reported QOL.

Key References for Prostate Cancer

Added this new section.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Key References for Prostate Cancer

Next section >
About This PDQ Summary